Moderna Announces The FDA Has Selected mRNA-3705 For The Support For Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program
Portfolio Pulse from Benzinga Newsdesk
Moderna announced that the FDA has selected its mRNA-3705 for the START Pilot Program, which aims to advance therapeutics for rare diseases.
June 06, 2024 | 11:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's mRNA-3705 has been selected by the FDA for the START Pilot Program, which is designed to support clinical trials for rare disease therapeutics. This selection could accelerate the development and approval process for mRNA-3705, potentially leading to new treatment options for rare diseases.
The FDA's selection of mRNA-3705 for the START Pilot Program is a significant regulatory milestone for Moderna. It indicates strong support for the clinical development of this therapeutic, which could lead to faster approval and market entry. This news is likely to positively impact Moderna's stock price in the short term as it enhances the company's pipeline and potential revenue streams.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100